102 related articles for article (PubMed ID: 26181790)
1. Oncolytic Herpes Simplex Virus Glioblastoma Therapy is Potentiated by Tumor Necrosis Factor-α Inhibition.
Pointer KB; Zhang RR; Kuo JS
Neurosurgery; 2015 Aug; 77(2):N18-20. PubMed ID: 26181790
[No Abstract] [Full Text] [Related]
2. The Impact of Macrophage- and Microglia-Secreted TNFα on Oncolytic HSV-1 Therapy in the Glioblastoma Tumor Microenvironment.
Meisen WH; Wohleb ES; Jaime-Ramirez AC; Bolyard C; Yoo JY; Russell L; Hardcastle J; Dubin S; Muili K; Yu J; Caligiuri M; Godbout J; Kaur B
Clin Cancer Res; 2015 Jul; 21(14):3274-85. PubMed ID: 25829396
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic virotherapy in glioblastoma patients induces a tumor macrophage phenotypic shift leading to an altered glioblastoma microenvironment.
van den Bossche WBL; Kleijn A; Teunissen CE; Voerman JSA; Teodosio C; Noske DP; van Dongen JJM; Dirven CMF; Lamfers MLM
Neuro Oncol; 2018 Oct; 20(11):1494-1504. PubMed ID: 29796615
[TBL] [Abstract][Full Text] [Related]
4. TGFβ Treatment Enhances Glioblastoma Virotherapy by Inhibiting the Innate Immune Response.
Han J; Chen X; Chu J; Xu B; Meisen WH; Chen L; Zhang L; Zhang J; He X; Wang QE; Chiocca EA; Kaur B; Caligiuri MA; Yu J
Cancer Res; 2015 Dec; 75(24):5273-82. PubMed ID: 26631269
[TBL] [Abstract][Full Text] [Related]
5. RE: stem cells loaded with multimechanistic oncolytic herpes simplex virus variants for brain tumor therapy.
Krause MN; Sancho-Martinez I; Izpisua Belmonte JC
J Natl Cancer Inst; 2015 Jan; 107(1):368. PubMed ID: 25473104
[No Abstract] [Full Text] [Related]
6. Oncolytic Virotherapy and the Tumor Microenvironment.
Berkey SE; Thorne SH; Bartlett DL
Adv Exp Med Biol; 2017; 1036():157-172. PubMed ID: 29275471
[TBL] [Abstract][Full Text] [Related]
7. How can we trick the immune system into overcoming the detrimental effects of oncolytic viral therapy to treat glioblastoma?
Meisen WH; Kaur B
Expert Rev Neurother; 2013 Apr; 13(4):341-3. PubMed ID: 23545048
[No Abstract] [Full Text] [Related]
8. Modulating the tumor microenvironment via oncolytic virus and PI3K inhibition synergistically restores immune checkpoint therapy response in PTEN-deficient glioblastoma.
Xing F; Xiao J; Wu J; Liang J; Lu X; Guo L; Li P; Hou P; Li C; Guo D
Signal Transduct Target Ther; 2021 Jul; 6(1):275. PubMed ID: 34315854
[No Abstract] [Full Text] [Related]
9. Active immunotherapy: oncolytic virus therapy using HSV-1.
Todo T
Adv Exp Med Biol; 2012; 746():178-86. PubMed ID: 22639168
[TBL] [Abstract][Full Text] [Related]
10. Blockade of transforming growth factor-β signaling enhances oncolytic herpes simplex virus efficacy in patient-derived recurrent glioblastoma models.
Esaki S; Nigim F; Moon E; Luk S; Kiyokawa J; Curry W; Cahill DP; Chi AS; Iafrate AJ; Martuza RL; Rabkin SD; Wakimoto H
Int J Cancer; 2017 Dec; 141(11):2348-2358. PubMed ID: 28801914
[TBL] [Abstract][Full Text] [Related]
11. Glioma immunoenvironment.
Hueng DY; Lin GJ; Sytwu HK
J Neurosurg; 2014 Apr; 120(4):1012-3. PubMed ID: 24438536
[No Abstract] [Full Text] [Related]
12. Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors.
Liu TC; Zhang T; Fukuhara H; Kuroda T; Todo T; Canron X; Bikfalvi A; Martuza RL; Kurtz A; Rabkin SD
Clin Cancer Res; 2006 Nov; 12(22):6791-9. PubMed ID: 17121900
[TBL] [Abstract][Full Text] [Related]
13. A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases.
Chen X; Han J; Chu J; Zhang L; Zhang J; Chen C; Chen L; Wang Y; Wang H; Yi L; Elder JB; Wang QE; He X; Kaur B; Chiocca EA; Yu J
Oncotarget; 2016 May; 7(19):27764-77. PubMed ID: 27050072
[TBL] [Abstract][Full Text] [Related]
14. Emerging immunotherapies for glioblastoma.
Desai R; Suryadevara CM; Batich KA; Farber SH; Sanchez-Perez L; Sampson JH
Expert Opin Emerg Drugs; 2016 Jun; 21(2):133-45. PubMed ID: 27223671
[TBL] [Abstract][Full Text] [Related]
15. Modulation of chemokines in the tumor microenvironment enhances oncolytic virotherapy for colorectal cancer.
Francis L; Guo ZS; Liu Z; Ravindranathan R; Urban JA; Sathaiah M; Magge D; Kalinski P; Bartlett DL
Oncotarget; 2016 Apr; 7(16):22174-85. PubMed ID: 26956047
[TBL] [Abstract][Full Text] [Related]
16. Understanding the role of cytokines in Glioblastoma Multiforme pathogenesis.
Zhu VF; Yang J; Lebrun DG; Li M
Cancer Lett; 2012 Mar; 316(2):139-50. PubMed ID: 22075379
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic targeting of tumor-associated macrophages and microglia in glioblastoma.
Bowman RL; Joyce JA
Immunotherapy; 2014; 6(6):663-6. PubMed ID: 25041027
[No Abstract] [Full Text] [Related]
18. Stem cells loaded with multimechanistic oncolytic herpes simplex virus variants for brain tumor therapy.
Duebgen M; Martinez-Quintanilla J; Tamura K; Hingtgen S; Redjal N; Wakimoto H; Shah K
J Natl Cancer Inst; 2014 Jun; 106(6):dju090. PubMed ID: 24838834
[TBL] [Abstract][Full Text] [Related]
19. Tumor-specific activity of cellular regulatory elements is down-regulated upon insertion into the herpes simplex virus genome.
Glass M; Söling A; Messerle M
J Neurovirol; 2008 Nov; 14(6):522-35. PubMed ID: 18979278
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapeutic Potential of Oncolytic H-1 Parvovirus: Hints of Glioblastoma Microenvironment Conversion towards Immunogenicity.
Angelova AL; Barf M; Geletneky K; Unterberg A; Rommelaere J
Viruses; 2017 Dec; 9(12):. PubMed ID: 29244745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
